Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Sep;80(9):1245-1246.
doi: 10.1136/annrheumdis-2021-220049. Epub 2021 Jun 7.

Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals

Oleg Melikhov  1 , Tatiana Kruglova  2 , Karine Lytkina  3 , Georgy Melkonyan  3 , Elena Prokhorovich  4 , Gleb Putsman  5 , Grigory Rodoman  5 , Arkady Vertkin  4 , Alena Zagrebneva  2 , Justin Stebbing  6
Affiliations
Observational Study

Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals

Oleg Melikhov et al. Ann Rheum Dis. 2021 Sep.
No abstract available

Keywords: COVID-19; cytokines; therapeutics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JS conflicts are disclosed here: https://www.nature.com/onc/editors.

References

    1. Richardson P, Griffin I, Tucker C, et al. . Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020;395:e30–1. 10.1016/S0140-6736(20)30304-4 - DOI - PMC - PubMed
    1. Stebbing J, Phelan A, Griffin I, et al. . COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020;20:400–2. 10.1016/S1473-3099(20)30132-8 - DOI - PMC - PubMed
    1. Stebbing J, Krishnan V, de Bono S, et al. . Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med 2020;12:e12697. 10.15252/emmm.202012697 - DOI - PMC - PubMed
    1. Stebbing J, Sánchez Nievas G, Falcone M, et al. . Jak inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv 2021;7:eabe4724. 10.1126/sciadv.abe4724 - DOI - PMC - PubMed
    1. Kalil AC, Patterson TF, Mehta AK. Baricitinib plus remdesevir for hospitalized patients with COVID-19. N Engl J Med 2020;4:795–807. - PMC - PubMed

LinkOut - more resources